InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology...

InterMune to Present at Goldman Sachs Healthcare and Needham & Co.
Biotechnology and Medical Technology Conferences

BRISBANE, Calif., June 6 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN) today announced that John Hodgman, Senior Vice President and
Chief Financial Officer of InterMune, will present at the Goldman Sachs
Twenty-Ninth Annual Global Healthcare Conference in Dana Point, Calif. on June
10, 2008 at 8:05 a.m. PDT (11:05 a.m. EDT). Mr. Hodgman will also present at
the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology
Conference in New York on June 12, 2008 at 9:30 a.m. EDT.
To access a live audio webcast of either presentation, investors and other
interested parties may log on to the investor relations page of InterMune's
corporate website at http://www.intermune.com. The company recommends logging
on to the site 15 minutes prior to the start of the presentations in order to
register or download any necessary software.
About InterMune
InterMune is a biotechnology company focused on the research, development
and commercialization of innovative therapies in pulmonology and hepatology.
InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis
(IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio
includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a
possible therapeutic candidate for the treatment of patients with IPF and a
research program focused on small molecules for pulmonary disease. The
hepatology portfolio includes the HCV protease inhibitor compound ITMN-191
(referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease
inhibitor research program, and a research program evaluating a new target in
hepatology. For additional information about InterMune and its R&D pipeline,
please visit http://www.intermune.com.
SOURCE InterMune, Inc.

Jim Goff of InterMune, Inc., +1-415-466-2228, jgoff@intermune.com